PDB Short entry for 2HXL HEADER TRANSFERASE 03-AUG-06 2HXL TITLE CRYSTAL STRUCTURE OF CHEK1 IN COMPLEX WITH INHIBITOR 1 COMPND MOL_ID: 1; COMPND 2 MOLECULE: SERINE/THREONINE-PROTEIN KINASE CHK1; COMPND 3 CHAIN: A; COMPND 4 FRAGMENT: CHEK1 KINASE DOMAIN; COMPND 5 EC: 2.7.11.1; COMPND 6 ENGINEERED: YES SOURCE MOL_ID: 1; SOURCE 2 ORGANISM_SCIENTIFIC: HOMO SAPIENS; SOURCE 3 ORGANISM_COMMON: HUMAN; SOURCE 4 ORGANISM_TAXID: 9606; SOURCE 5 GENE: CHEK1; SOURCE 6 EXPRESSION_SYSTEM: SPODOPTERA FRUGIPERDA; SOURCE 7 EXPRESSION_SYSTEM_COMMON: FALL ARMYWORM; SOURCE 8 EXPRESSION_SYSTEM_TAXID: 7108; SOURCE 9 EXPRESSION_SYSTEM_PLASMID: PRAD2030 KEYWDS CHEK1, KINASE, CELL CYCLE CHECKPOINT, TRANSFERASE EXPDTA X-RAY DIFFRACTION AUTHOR Y.YAN REVDAT 3 30-AUG-23 2HXL 1 REMARK SEQADV REVDAT 2 24-FEB-09 2HXL 1 VERSN REVDAT 1 19-JUN-07 2HXL 0 JRNL AUTH S.HUANG,R.M.GARBACCIO,M.E.FRALEY,J.STEEN,C.KREATSOULAS, JRNL AUTH 2 G.HARTMAN,S.STIRDIVANT,B.DRAKAS,K.RICKERT,E.WALSH, JRNL AUTH 3 K.HAMILTON,C.A.BUSER,J.HARDWICK,X.MAO,M.ABRAMS,S.BECK,W.TAO, JRNL AUTH 4 R.LOBELL,L.SEPP-LORENZINO,Y.YAN,M.IKUTA,J.Z.MURPHY, JRNL AUTH 5 V.SARDANA,S.MUNSHI,L.KUO,M.REILLY,E.MAHAN JRNL TITL DEVELOPMENT OF 6-SUBSTITUTED INDOLYLQUINOLINONES AS POTENT JRNL TITL 2 CHEK1 KINASE INHIBITORS. JRNL REF BIOORG.MED.CHEM.LETT. V. 16 5907 2006 JRNL REFN ISSN 0960-894X JRNL PMID 16990002 JRNL DOI 10.1016/J.BMCL.2006.08.053 REMARK 2 REMARK 2 RESOLUTION. 1.80 ANGSTROMS. REMARK 3 REMARK 3 REFINEMENT. REMARK 3 PROGRAM : CNS REMARK 3 AUTHORS : BRUNGER,ADAMS,CLORE,DELANO,GROS,GROSSE- REMARK 3 : KUNSTLEVE,JIANG,KUSZEWSKI,NILGES,PANNU, REMARK 3 : READ,RICE,SIMONSON,WARREN REMARK 3 REMARK 3 REFINEMENT TARGET : ENGH & HUBER REMARK 3 REMARK 3 DATA USED IN REFINEMENT. REMARK 3 RESOLUTION RANGE HIGH (ANGSTROMS) : 1.80 REMARK 3 RESOLUTION RANGE LOW (ANGSTROMS) : 40.00 REMARK 3 DATA CUTOFF (SIGMA(F)) : 0.000 REMARK 3 DATA CUTOFF HIGH (ABS(F)) : NULL REMARK 3 DATA CUTOFF LOW (ABS(F)) : NULL REMARK 3 COMPLETENESS (WORKING+TEST) (%) : 98.0 REMARK 3 NUMBER OF REFLECTIONS : 30747 REMARK 3 REMARK 3 FIT TO DATA USED IN REFINEMENT. REMARK 3 CROSS-VALIDATION METHOD : NULL REMARK 3 FREE R VALUE TEST SET SELECTION : RAMDOM REMARK 3 R VALUE (WORKING SET) : 0.240 REMARK 3 FREE R VALUE : 0.270 REMARK 3 FREE R VALUE TEST SET SIZE (%) : NULL REMARK 3 FREE R VALUE TEST SET COUNT : 1528 REMARK 3 ESTIMATED ERROR OF FREE R VALUE : NULL REMARK 3 REMARK 3 FIT IN THE HIGHEST RESOLUTION BIN. REMARK 3 TOTAL NUMBER OF BINS USED : NULL REMARK 3 BIN RESOLUTION RANGE HIGH (A) : NULL REMARK 3 BIN RESOLUTION RANGE LOW (A) : NULL REMARK 3 BIN COMPLETENESS (WORKING+TEST) (%) : NULL REMARK 3 REFLECTIONS IN BIN (WORKING SET) : NULL REMARK 3 BIN R VALUE (WORKING SET) : NULL REMARK 3 BIN FREE R VALUE : NULL REMARK 3 BIN FREE R VALUE TEST SET SIZE (%) : NULL REMARK 3 BIN FREE R VALUE TEST SET COUNT : NULL REMARK 3 ESTIMATED ERROR OF BIN FREE R VALUE : NULL REMARK 3 REMARK 3 NUMBER OF NON-HYDROGEN ATOMS USED IN REFINEMENT. REMARK 3 PROTEIN ATOMS : 2202 REMARK 3 NUCLEIC ACID ATOMS : 0 REMARK 3 HETEROGEN ATOMS : 29 REMARK 3 SOLVENT ATOMS : 115 REMARK 3 REMARK 3 B VALUES. REMARK 3 FROM WILSON PLOT (A**2) : NULL REMARK 3 MEAN B VALUE (OVERALL, A**2) : NULL REMARK 3 OVERALL ANISOTROPIC B VALUE. REMARK 3 B11 (A**2) : NULL REMARK 3 B22 (A**2) : NULL REMARK 3 B33 (A**2) : NULL REMARK 3 B12 (A**2) : NULL REMARK 3 B13 (A**2) : NULL REMARK 3 B23 (A**2) : NULL REMARK 3 REMARK 3 ESTIMATED COORDINATE ERROR. REMARK 3 ESD FROM LUZZATI PLOT (A) : NULL REMARK 3 ESD FROM SIGMAA (A) : NULL REMARK 3 LOW RESOLUTION CUTOFF (A) : NULL REMARK 3 REMARK 3 CROSS-VALIDATED ESTIMATED COORDINATE ERROR. REMARK 3 ESD FROM C-V LUZZATI PLOT (A) : NULL REMARK 3 ESD FROM C-V SIGMAA (A) : NULL REMARK 3 REMARK 3 RMS DEVIATIONS FROM IDEAL VALUES. REMARK 3 BOND LENGTHS (A) : 0.008 REMARK 3 BOND ANGLES (DEGREES) : 1.560 REMARK 3 DIHEDRAL ANGLES (DEGREES) : NULL REMARK 3 IMPROPER ANGLES (DEGREES) : NULL REMARK 3 REMARK 3 ISOTROPIC THERMAL MODEL : NULL REMARK 3 REMARK 3 ISOTROPIC THERMAL FACTOR RESTRAINTS. RMS SIGMA REMARK 3 MAIN-CHAIN BOND (A**2) : NULL ; NULL REMARK 3 MAIN-CHAIN ANGLE (A**2) : NULL ; NULL REMARK 3 SIDE-CHAIN BOND (A**2) : NULL ; NULL REMARK 3 SIDE-CHAIN ANGLE (A**2) : NULL ; NULL REMARK 3 REMARK 3 BULK SOLVENT MODELING. REMARK 3 METHOD USED : NULL REMARK 3 KSOL : NULL REMARK 3 BSOL : NULL REMARK 3 REMARK 3 NCS MODEL : NULL REMARK 3 REMARK 3 NCS RESTRAINTS. RMS SIGMA/WEIGHT REMARK 3 GROUP 1 POSITIONAL (A) : NULL ; NULL REMARK 3 GROUP 1 B-FACTOR (A**2) : NULL ; NULL REMARK 3 REMARK 3 PARAMETER FILE 1 : NULL REMARK 3 TOPOLOGY FILE 1 : NULL REMARK 3 REMARK 3 OTHER REFINEMENT REMARKS: NULL REMARK 4 REMARK 4 2HXL COMPLIES WITH FORMAT V. 3.30, 13-JUL-11 REMARK 100 REMARK 100 THIS ENTRY HAS BEEN PROCESSED BY RCSB ON 07-AUG-06. REMARK 100 THE DEPOSITION ID IS D_1000038879. REMARK 200 REMARK 200 EXPERIMENTAL DETAILS REMARK 200 EXPERIMENT TYPE : X-RAY DIFFRACTION REMARK 200 DATE OF DATA COLLECTION : 18-AUG-04 REMARK 200 TEMPERATURE (KELVIN) : 100 REMARK 200 PH : 6.8 REMARK 200 NUMBER OF CRYSTALS USED : 1 REMARK 200 REMARK 200 SYNCHROTRON (Y/N) : N REMARK 200 RADIATION SOURCE : ROTATING ANODE REMARK 200 BEAMLINE : NULL REMARK 200 X-RAY GENERATOR MODEL : RIGAKU REMARK 200 MONOCHROMATIC OR LAUE (M/L) : M REMARK 200 WAVELENGTH OR RANGE (A) : 1.5418 REMARK 200 MONOCHROMATOR : NULL REMARK 200 OPTICS : BLUE CONFOCAL OPTICAL SYSTEM REMARK 200 REMARK 200 DETECTOR TYPE : IMAGE PLATE REMARK 200 DETECTOR MANUFACTURER : RIGAKU RAXIS IV REMARK 200 INTENSITY-INTEGRATION SOFTWARE : D*TREK REMARK 200 DATA SCALING SOFTWARE : D*TREK REMARK 200 REMARK 200 NUMBER OF UNIQUE REFLECTIONS : 30801 REMARK 200 RESOLUTION RANGE HIGH (A) : 1.800 REMARK 200 RESOLUTION RANGE LOW (A) : 45.000 REMARK 200 REJECTION CRITERIA (SIGMA(I)) : 0.000 REMARK 200 REMARK 200 OVERALL. REMARK 200 COMPLETENESS FOR RANGE (%) : 98.0 REMARK 200 DATA REDUNDANCY : 6.100 REMARK 200 R MERGE (I) : 0.06700 REMARK 200 R SYM (I) : 0.06700 REMARK 200 <I/SIGMA(I)> FOR THE DATA SET : 12.0000 REMARK 200 REMARK 200 IN THE HIGHEST RESOLUTION SHELL. REMARK 200 HIGHEST RESOLUTION SHELL, RANGE HIGH (A) : 1.80 REMARK 200 HIGHEST RESOLUTION SHELL, RANGE LOW (A) : 1.86 REMARK 200 COMPLETENESS FOR SHELL (%) : 96.0 REMARK 200 DATA REDUNDANCY IN SHELL : 6.10 REMARK 200 R MERGE FOR SHELL (I) : 0.48200 REMARK 200 R SYM FOR SHELL (I) : 0.48200 REMARK 200 <I/SIGMA(I)> FOR SHELL : 3.100 REMARK 200 REMARK 200 DIFFRACTION PROTOCOL: SINGLE WAVELENGTH REMARK 200 METHOD USED TO DETERMINE THE STRUCTURE: FOURIER SYNTHESIS REMARK 200 SOFTWARE USED: CNS REMARK 200 STARTING MODEL: 1IA8 REMARK 200 REMARK 200 REMARK: NULL REMARK 280 REMARK 280 CRYSTAL REMARK 280 SOLVENT CONTENT, VS (%): 47.20 REMARK 280 MATTHEWS COEFFICIENT, VM (ANGSTROMS**3/DA): 2.33 REMARK 280 REMARK 280 CRYSTALLIZATION CONDITIONS: 13% PEG 8K, 0.1M AMMONIUM SULFATE, 2% REMARK 280 GLYCEROL, 0.1M CACODYLATE BUFFER AT PH6.8, VAPOR DIFFUSION, REMARK 280 HANGING DROP, TEMPERATURE 298K REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY REMARK 290 SYMMETRY OPERATORS FOR SPACE GROUP: P 1 21 1 REMARK 290 REMARK 290 SYMOP SYMMETRY REMARK 290 NNNMMM OPERATOR REMARK 290 1555 X,Y,Z REMARK 290 2555 -X,Y+1/2,-Z REMARK 290 REMARK 290 WHERE NNN -> OPERATOR NUMBER REMARK 290 MMM -> TRANSLATION VECTOR REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY TRANSFORMATIONS REMARK 290 THE FOLLOWING TRANSFORMATIONS OPERATE ON THE ATOM/HETATM REMARK 290 RECORDS IN THIS ENTRY TO PRODUCE CRYSTALLOGRAPHICALLY REMARK 290 RELATED MOLECULES. REMARK 290 SMTRY1 1 1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 1 0.000000 1.000000 0.000000 0.00000 REMARK 290 SMTRY3 1 0.000000 0.000000 1.000000 0.00000 REMARK 290 SMTRY1 2 -1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 2 0.000000 1.000000 0.000000 32.82000 REMARK 290 SMTRY3 2 0.000000 0.000000 -1.000000 0.00000 REMARK 290 REMARK 290 REMARK: NULL REMARK 300 REMARK 300 BIOMOLECULE: 1 REMARK 300 SEE REMARK 350 FOR THE AUTHOR PROVIDED AND/OR PROGRAM REMARK 300 GENERATED ASSEMBLY INFORMATION FOR THE STRUCTURE IN REMARK 300 THIS ENTRY. THE REMARK MAY ALSO PROVIDE INFORMATION ON REMARK 300 BURIED SURFACE AREA. REMARK 350 REMARK 350 COORDINATES FOR A COMPLETE MULTIMER REPRESENTING THE KNOWN REMARK 350 BIOLOGICALLY SIGNIFICANT OLIGOMERIZATION STATE OF THE REMARK 350 MOLECULE CAN BE GENERATED BY APPLYING BIOMT TRANSFORMATIONS REMARK 350 GIVEN BELOW. BOTH NON-CRYSTALLOGRAPHIC AND REMARK 350 CRYSTALLOGRAPHIC OPERATIONS ARE GIVEN. REMARK 350 REMARK 350 BIOMOLECULE: 1 REMARK 350 AUTHOR DETERMINED BIOLOGICAL UNIT: MONOMERIC REMARK 350 APPLY THE FOLLOWING TO CHAINS: A REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 465 REMARK 465 MISSING RESIDUES REMARK 465 THE FOLLOWING RESIDUES WERE NOT LOCATED IN THE REMARK 465 EXPERIMENT. (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN REMARK 465 IDENTIFIER; SSSEQ=SEQUENCE NUMBER; I=INSERTION CODE.) REMARK 465 REMARK 465 M RES C SSSEQI REMARK 465 ALA A 45 REMARK 465 VAL A 46 REMARK 465 ASP A 47 REMARK 465 ARG A 277 REMARK 465 VAL A 278 REMARK 465 THR A 279 REMARK 465 SER A 280 REMARK 465 GLY A 281 REMARK 465 GLY A 282 REMARK 465 VAL A 283 REMARK 465 SER A 284 REMARK 465 GLU A 285 REMARK 465 SER A 286 REMARK 465 PRO A 287 REMARK 465 SER A 288 REMARK 465 GLY A 289 REMARK 465 PHE A 290 REMARK 465 SER A 291 REMARK 465 LYS A 292 REMARK 465 HIS A 293 REMARK 465 ILE A 294 REMARK 465 GLN A 295 REMARK 465 SER A 296 REMARK 465 ASN A 297 REMARK 465 LEU A 298 REMARK 465 ASP A 299 REMARK 465 PHE A 300 REMARK 465 SER A 301 REMARK 465 PRO A 302 REMARK 465 VAL A 303 REMARK 465 ASN A 304 REMARK 465 SER A 305 REMARK 465 ALA A 306 REMARK 465 SER A 307 REMARK 465 ARG A 308 REMARK 465 THR A 309 REMARK 465 PRO A 310 REMARK 465 GLY A 311 REMARK 465 SER A 312 REMARK 465 GLY A 313 REMARK 465 TRP A 314 REMARK 465 SER A 315 REMARK 465 LYS A 316 REMARK 465 GLU A 317 REMARK 465 HIS A 318 REMARK 465 HIS A 319 REMARK 465 HIS A 320 REMARK 465 HIS A 321 REMARK 465 HIS A 322 REMARK 465 HIS A 323 REMARK 470 REMARK 470 MISSING ATOM REMARK 470 THE FOLLOWING RESIDUES HAVE MISSING ATOMS (M=MODEL NUMBER; REMARK 470 RES=RESIDUE NAME; C=CHAIN IDENTIFIER; SSEQ=SEQUENCE NUMBER; REMARK 470 I=INSERTION CODE): REMARK 470 M RES CSSEQI ATOMS REMARK 470 TYR A 20 CG CD1 CD2 CE1 CE2 CZ OH REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: COVALENT BOND ANGLES REMARK 500 REMARK 500 THE STEREOCHEMICAL PARAMETERS OF THE FOLLOWING RESIDUES REMARK 500 HAVE VALUES WHICH DEVIATE FROM EXPECTED VALUES BY MORE REMARK 500 THAN 6*RMSD (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN REMARK 500 IDENTIFIER; SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT: (10X,I3,1X,A3,1X,A1,I4,A1,3(1X,A4,2X),12X,F5.1) REMARK 500 REMARK 500 EXPECTED VALUES PROTEIN: ENGH AND HUBER, 1999 REMARK 500 EXPECTED VALUES NUCLEIC ACID: CLOWNEY ET AL 1996 REMARK 500 REMARK 500 M RES CSSEQI ATM1 ATM2 ATM3 REMARK 500 PRO A 4 C - N - CA ANGL. DEV. = 10.5 DEGREES REMARK 500 REMARK 500 REMARK: NULL REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: TORSION ANGLES REMARK 500 REMARK 500 TORSION ANGLES OUTSIDE THE EXPECTED RAMACHANDRAN REGIONS: REMARK 500 (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN IDENTIFIER; REMARK 500 SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT:(10X,I3,1X,A3,1X,A1,I4,A1,4X,F7.2,3X,F7.2) REMARK 500 REMARK 500 EXPECTED VALUES: GJ KLEYWEGT AND TA JONES (1996). PHI/PSI- REMARK 500 CHOLOGY: RAMACHANDRAN REVISITED. STRUCTURE 4, 1395 - 1400 REMARK 500 REMARK 500 M RES CSSEQI PSI PHI REMARK 500 ARG A 75 -71.28 -69.98 REMARK 500 GLU A 76 79.81 44.15 REMARK 500 ILE A 100 -51.46 -122.66 REMARK 500 ASP A 130 45.58 -149.47 REMARK 500 ASP A 148 92.55 70.33 REMARK 500 ASN A 165 -15.41 -145.43 REMARK 500 ASN A 229 -67.97 -10.18 REMARK 500 ASP A 235 135.66 105.12 REMARK 500 LEU A 269 -50.20 -140.79 REMARK 500 ARG A 275 79.86 53.54 REMARK 500 REMARK 500 REMARK: NULL REMARK 800 REMARK 800 SITE REMARK 800 SITE_IDENTIFIER: AC1 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE 422 A 324 DBREF 2HXL A 2 307 UNP O14757 CHK1_HUMAN 2 307 SEQADV 2HXL ARG A 308 UNP O14757 CLONING ARTIFACT SEQADV 2HXL THR A 309 UNP O14757 CLONING ARTIFACT SEQADV 2HXL PRO A 310 UNP O14757 CLONING ARTIFACT SEQADV 2HXL GLY A 311 UNP O14757 CLONING ARTIFACT SEQADV 2HXL SER A 312 UNP O14757 CLONING ARTIFACT SEQADV 2HXL GLY A 313 UNP O14757 CLONING ARTIFACT SEQADV 2HXL TRP A 314 UNP O14757 CLONING ARTIFACT SEQADV 2HXL SER A 315 UNP O14757 CLONING ARTIFACT SEQADV 2HXL LYS A 316 UNP O14757 CLONING ARTIFACT SEQADV 2HXL GLU A 317 UNP O14757 CLONING ARTIFACT SEQADV 2HXL HIS A 318 UNP O14757 EXPRESSION TAG SEQADV 2HXL HIS A 319 UNP O14757 EXPRESSION TAG SEQADV 2HXL HIS A 320 UNP O14757 EXPRESSION TAG SEQADV 2HXL HIS A 321 UNP O14757 EXPRESSION TAG SEQADV 2HXL HIS A 322 UNP O14757 EXPRESSION TAG SEQADV 2HXL HIS A 323 UNP O14757 EXPRESSION TAG SEQRES 1 A 322 ALA VAL PRO PHE VAL GLU ASP TRP ASP LEU VAL GLN THR SEQRES 2 A 322 LEU GLY GLU GLY ALA TYR GLY GLU VAL GLN LEU ALA VAL SEQRES 3 A 322 ASN ARG VAL THR GLU GLU ALA VAL ALA VAL LYS ILE VAL SEQRES 4 A 322 ASP MET LYS ARG ALA VAL ASP CYS PRO GLU ASN ILE LYS SEQRES 5 A 322 LYS GLU ILE CYS ILE ASN LYS MET LEU ASN HIS GLU ASN SEQRES 6 A 322 VAL VAL LYS PHE TYR GLY HIS ARG ARG GLU GLY ASN ILE SEQRES 7 A 322 GLN TYR LEU PHE LEU GLU TYR CYS SER GLY GLY GLU LEU SEQRES 8 A 322 PHE ASP ARG ILE GLU PRO ASP ILE GLY MET PRO GLU PRO SEQRES 9 A 322 ASP ALA GLN ARG PHE PHE HIS GLN LEU MET ALA GLY VAL SEQRES 10 A 322 VAL TYR LEU HIS GLY ILE GLY ILE THR HIS ARG ASP ILE SEQRES 11 A 322 LYS PRO GLU ASN LEU LEU LEU ASP GLU ARG ASP ASN LEU SEQRES 12 A 322 LYS ILE SER ASP PHE GLY LEU ALA THR VAL PHE ARG TYR SEQRES 13 A 322 ASN ASN ARG GLU ARG LEU LEU ASN LYS MET CYS GLY THR SEQRES 14 A 322 LEU PRO TYR VAL ALA PRO GLU LEU LEU LYS ARG ARG GLU SEQRES 15 A 322 PHE HIS ALA GLU PRO VAL ASP VAL TRP SER CYS GLY ILE SEQRES 16 A 322 VAL LEU THR ALA MET LEU ALA GLY GLU LEU PRO TRP ASP SEQRES 17 A 322 GLN PRO SER ASP SER CYS GLN GLU TYR SER ASP TRP LYS SEQRES 18 A 322 GLU LYS LYS THR TYR LEU ASN PRO TRP LYS LYS ILE ASP SEQRES 19 A 322 SER ALA PRO LEU ALA LEU LEU HIS LYS ILE LEU VAL GLU SEQRES 20 A 322 ASN PRO SER ALA ARG ILE THR ILE PRO ASP ILE LYS LYS SEQRES 21 A 322 ASP ARG TRP TYR ASN LYS PRO LEU LYS LYS GLY ALA LYS SEQRES 22 A 322 ARG PRO ARG VAL THR SER GLY GLY VAL SER GLU SER PRO SEQRES 23 A 322 SER GLY PHE SER LYS HIS ILE GLN SER ASN LEU ASP PHE SEQRES 24 A 322 SER PRO VAL ASN SER ALA SER ARG THR PRO GLY SER GLY SEQRES 25 A 322 TRP SER LYS GLU HIS HIS HIS HIS HIS HIS HET 422 A 324 29 HETNAM 422 3-(5-{[4-(AMINOMETHYL)PIPERIDIN-1-YL]METHYL}-1H-INDOL- HETNAM 2 422 2-YL)-1H-INDAZOLE-6-CARBONITRILE FORMUL 2 422 C23 H24 N6 FORMUL 3 HOH *115(H2 O) HELIX 1 1 CYS A 48 MET A 61 1 14 HELIX 2 2 PHE A 93 ILE A 96 5 4 HELIX 3 3 PRO A 103 ILE A 124 1 22 HELIX 4 4 LYS A 132 GLU A 134 5 3 HELIX 5 5 THR A 170 VAL A 174 5 5 HELIX 6 6 ALA A 175 ARG A 181 1 7 HELIX 7 7 HIS A 185 GLY A 204 1 20 HELIX 8 8 CYS A 215 GLU A 223 1 9 HELIX 9 9 PRO A 230 ILE A 234 5 5 HELIX 10 10 ASP A 235 LEU A 246 1 12 HELIX 11 11 THR A 255 LYS A 260 1 6 SHEET 1 A 5 TRP A 9 GLU A 17 0 SHEET 2 A 5 GLY A 21 ASN A 28 -1 O VAL A 23 N GLY A 16 SHEET 3 A 5 ALA A 34 ASP A 41 -1 O ILE A 39 N GLU A 22 SHEET 4 A 5 ILE A 79 GLU A 85 -1 O LEU A 84 N ALA A 36 SHEET 5 A 5 PHE A 70 ARG A 74 -1 N TYR A 71 O PHE A 83 SHEET 1 B 3 GLY A 90 GLU A 91 0 SHEET 2 B 3 LEU A 136 LEU A 138 -1 O LEU A 138 N GLY A 90 SHEET 3 B 3 LEU A 144 ILE A 146 -1 O LYS A 145 N LEU A 137 SHEET 1 C 2 ILE A 126 THR A 127 0 SHEET 2 C 2 THR A 153 VAL A 154 -1 O THR A 153 N THR A 127 SHEET 1 D 2 ARG A 156 TYR A 157 0 SHEET 2 D 2 ARG A 160 GLU A 161 -1 O ARG A 160 N TYR A 157 SITE 1 AC1 12 GLN A 13 THR A 14 LEU A 15 ALA A 36 SITE 2 AC1 12 LEU A 84 GLU A 85 TYR A 86 CYS A 87 SITE 3 AC1 12 GLY A 90 LEU A 137 ASP A 148 HOH A 418 CRYST1 45.100 65.640 58.140 90.00 94.82 90.00 P 1 21 1 2 ORIGX1 1.000000 0.000000 0.000000 0.00000 ORIGX2 0.000000 1.000000 0.000000 0.00000 ORIGX3 0.000000 0.000000 1.000000 0.00000 SCALE1 0.022173 0.000000 0.001870 0.00000 SCALE2 0.000000 0.015235 0.000000 0.00000 SCALE3 0.000000 0.000000 0.017261 0.00000